Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.61 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.61 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | FDPS | P14324 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.48 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.48 |
| ▸ | MMP2 | P08253 | 2/20 | 0.48 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | RAD52 | P43351 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL134169 | 1.00 | FFAR1 (0.61) | FFAR1FFAR4GPR84NFKB1FDPS | |
| SCHEMBL7661582 | 1.00 | FFAR1 (0.61) | FFAR1FFAR4GPR84NFKB1FDPS | |
| SCHEMBL378916 | 1.00 | FFAR1 (0.61) | FFAR1FFAR4GPR84NFKB1FDPS | |
| SCHEMBL77285 | 1.00 | FFAR1 (0.61) | FFAR1FFAR4GPR84NFKB1FDPS | |
| SCHEMBL12152020 | 1.00 | FFAR1 (0.61) | FFAR1FFAR4GPR84NFKB1FDPS | |
| SCHEMBL378816 | 1.00 | FFAR1 (0.61) | FFAR1FFAR4GPR84NFKB1FDPS | |
| SCHEMBL2990323 | 1.00 | FFAR1 (0.61) | FFAR1FFAR4GPR84NFKB1FDPS | |
| SCHEMBL105856 | 1.00 | FFAR1 (0.61) | FFAR1FFAR4GPR84NFKB1FDPS | |
| SCHEMBL22395574 | 1.00 | FFAR1 (0.61) | FFAR1FFAR4GPR84NFKB1FDPS | |
| SCHEMBL12537419 | 1.00 | FFAR1 (0.61) | FFAR1FFAR4GPR84NFKB1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6384228-B2 | EPIBATIDINE; ANALGESICS; ANIMAL EXTRACTS | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2002-05-07 | — | — | US | disclosed |
| US-20020010339-A1 | METHOD FOR SYNTHESIS OF HALOPYRIDYL-ACYCLOPENTANE DERIVATIVE AND INTERMEDIATE THEREOF | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2002-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010339-A1 | METHOD FOR SYNTHESIS OF HALOPYRIDYL-ACYCLOPENTANE DERIVATIVE AND INTERMEDIATE THEREOF | DHPS, ALAD, HAAO | FFAR1 1252/4885FFAR4 1373/4885GPR84 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.